

Adjuvant polychemotherapy in oestrogen-receptor-poor breast cancer: meta-analysis of individual patient data from the randomised trials

The Lancet 2008; 371: 29-40

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

Web site figures


Each figure is in three parts, corresponding to the three endpoints: (i) recurrence, (ii) breast cancer mortality and (iii) death from any cause.

- Web Fig. 1** Polychemotherapy versus not in ER-poor disease, subdivided first by type of comparison (absence or presence of tamoxifen in both treatment groups) and then by age at randomisation: event rate ratios for recurrence, breast cancer mortality and death from any cause
- Web Fig. 2** Polychemotherapy versus not in ER-poor disease, subdivided first by age at randomisation and then by type of comparison (absence or presence of tamoxifen in both treatment groups): event rate ratios for recurrence, breast cancer mortality and death from any cause
- Web Fig. 3** Tamoxifen versus not in ER-poor disease, subdivided first by age at randomisation and then by type of comparison (absence or presence of chemotherapy in both treatment groups): event rate ratios for recurrence, breast cancer mortality and death from any cause
- Web Fig. 4** Polychemotherapy versus not in ER-poor disease, by type of comparison (absence or presence of tamoxifen in both treatment groups) and age at randomisation: 10-year probabilities of recurrence, breast cancer mortality and death from any cause
- Web Fig. 5** Polychemotherapy versus not in ER-poor disease, by type of comparison (absence or presence of tamoxifen in both treatment groups) for patients with entry age < 50: 10-year probabilities of recurrence, breast cancer mortality and death from any cause
- Web Fig. 6** Polychemotherapy versus not in ER-poor disease, by type of comparison (absence or presence of tamoxifen in both treatment groups) for patients with entry ages 50-69: 10-year probabilities of recurrence, breast cancer mortality and death from any cause
- Web Fig. 7** Polychemotherapy versus not in ER-poor disease, subdivided first by age at


randomisation and then by nodal status: event rate ratios for recurrence, breast cancer mortality and death from any cause

- Web Fig. 8** Polychemotherapy versus not in ER-poor disease, by various subgroups: event rate ratios for recurrence, breast cancer mortality and death from any cause
- Web Fig. 9** Polychemotherapy versus not in ER-poor disease: trial details and recurrence, breast cancer mortality and all-cause mortality rate ratios in each of 46 separate trials
- Web Fig. 10** Tamoxifen versus not in ER-poor disease: trial details and recurrence, breast cancer mortality and all-cause mortality rate ratios in each of 50 separate trials
- Web Fig. 11** Perioperative polychemotherapy versus no adjuvant cytotoxic in ER-poor disease, subdivided by nodal and menopausal status: trial details and recurrence, breast cancer mortality and all-cause mortality rate ratios in each of 4 separate trials


Web Fig. 1(i). Polychemotherapy versus not in ER-poor disease, subdivided first by type of comparison (absence or presence of tamoxifen in both treatment groups) and then by age at randomisation: event rate ratios for recurrence




Web Fig. 1(ii). Polychemotherapy versus not in ER-poor disease, subdivided first by type of comparison (absence or presence of tamoxifen in both treatment groups) and then by age at randomisation: event rate ratios for breast cancer mortality




Web Fig. 1(iii). Polychemotherapy versus not in ER-poor disease, subdivided first by type of comparison (absence or presence of tamoxifen in both treatment groups) and then by age at randomisation: event rate ratios for death from any cause




Web Fig. 2(i). Polychemotherapy versus not in ER-poor disease, subdivided first by age at randomisation and then by type of comparison (absence or presence of tamoxifen in both treatment groups): event rate ratios for recurrence




Web Fig. 2(ii). Polychemotherapy versus not in ER-poor disease, subdivided first by age at randomisation and then by type of comparison (absence or presence of tamoxifen in both treatment groups): event rate ratios for breast cancer mortality



Web Fig. 2(iii). Polychemotherapy versus not in ER-poor disease, subdivided first by age at randomisation and then by type of comparison (absence or presence of tamoxifen in both treatment groups): event rate ratios for death from any cause




Web Fig. 3(i). Tamoxifen versus not in ER-poor disease, subdivided first by age at randomisation and then by type of comparison (absence or presence of chemotherapy* in both treatment groups): event rate ratios for recurrence




* In the tamoxifen versus not analyses, 3 of the 32 trials were of single-agent chemotherapy.

Web Fig. 3(ii). Tamoxifen versus not in ER-poor disease, subdivided first by age at randomisation and then by type of comparison (absence or presence of chemotherapy* in both treatment groups): event rate ratios for breast cancer mortality




* In the tamoxifen versus not analyses, 3 of the 32 trials were of single-agent chemotherapy.

Web Fig. 3(iii). Tamoxifen versus not in ER-poor disease, subdivided first by age at randomisation and then by type of comparison (absence or presence of chemotherapy* in both treatment groups): event rate ratios for death from any cause




* In the tamoxifen versus not analyses, 3 of the 32 trials were of single-agent chemotherapy.


Web Fig. 4(i). Polychemotherapy versus not in ER-poor disease, by type of comparison (absence or presence of tamoxifen in both treatment groups) and age at randomisation: 10-year probabilities of recurrence



Web Fig. 4(ii). Polychemotherapy versus not in ER-poor disease, by type of comparison (absence or presence of tamoxifen in both treatment groups) and age at randomisation: 10-year probabilities of breast cancer mortality



Web Fig. 4(iii). Polychemotherapy versus not in ER-poor disease, by type of comparison (absence or presence of tamoxifen in both treatment groups) and age at randomisation: 10-year probabilities of death from any cause




Web Fig. 5. Polychemotherapy versus not in ER-poor disease, by type of comparison (absence or presence of tamoxifen in both treatment groups) for patients with entry age < 50: 10-year probabilities of (i) recurrence, (ii) breast cancer mortality and (iii) death from any cause

(i) Recurrence

(ii) Breast cancer mortality

(iii) Death from any cause




Web Fig. 6. Polychemotherapy versus not in ER-poor disease, by type of comparison (absence or presence of tamoxifen in both treatment groups) for patients with entry ages 50-69: 10-year probabilities of (i) recurrence, (ii) breast cancer mortality and (iii) death from any cause


(i) Recurrence

(ii) Breast cancer mortality


(iii) Death from any cause




Web Fig. 7(i). Polychemotherapy versus not in ER-poor disease, subdivided first by age at randomisation and then by nodal status: event rate ratios for recurrence




Web Fig. 7(ii). Polychemotherapy versus not in ER-poor disease, subdivided first by age at randomisation and then by nodal status: event rate ratios for breast cancer mortality




Web Fig. 7(iii). Polychemotherapy versus not in ER-poor disease, subdivided first by age at randomisation and then by nodal status: event rate ratios for death from any cause




Web Fig. 8(i). Polychemotherapy versus not in ER-poor disease, by various subgroups: event rate ratios for recurrence




Web Fig. 8(ii). Polychemotherapy versus not in ER-poor disease, by various subgroups: event rate ratios for breast cancer mortality




Web Fig. 8(iii). Polychemotherapy versus not in ER-poor disease, by various subgroups: event rate ratios for death from any cause




Web Fig. 9(i). Polychemotherapy versus not in ER-poor disease: trial details and recurrence rate ratios in each of 46 separate trials




Web Fig. 9(ii). Polychemotherapy versus not in ER-poor disease: trial details and breast cancer mortality rate ratios in each of 46 separate trials




Web Fig. 9(iii). Polychemotherapy versus not in ER-poor disease: trial details and all-cause mortality rate ratios in each of 46 separate trials




Web Fig. 10(i). Tamoxifen versus not in ER-poor disease: trial details and recurrence rate ratios in each of 50 separate trials




Web Fig. 10(ii). Tamoxifen versus not in ER-poor disease: trial details and breast cancer mortality rate ratios in each of 50 separate trials



Web Fig. 10(iii). Tamoxifen versus not in ER-poor disease: trial details and all-cause mortality rate ratios in each of 50 separate trials




Web Fig. 11(i). Perioperative polychemotherapy (PeCT) versus no adjuvant cytotoxic in ER-poor disease, subdivided by nodal and menopausal status: trial details and recurrence rate ratios in each of 4 separate trials



* Includes perimenopausal (and age < 50 with unknown status)

† Hypothesis generator


Web Fig. 11(ii). Perioperative polychemotherapy (PeCT) versus no adjuvant cytotoxic in ER-poor disease, subdivided by nodal and menopausal status: trial details and breast cancer mortality rate ratios in each of 4 separate trials



* Includes perimenopausal (and age < 50 with unknown status)

† Hypothesis generator

Web Fig. 11(iii). Perioperative polychemotherapy (PeCT) versus no adjuvant cytotoxic in ER-poor disease, subdivided by nodal and menopausal status: trial details and all-cause mortality rate ratios in each of 4 separate trials



* Includes perimenopausal (and age < 50 with unknown status)

† Hypothesis generator